1. Home
  2. CAPR vs HELE Comparison

CAPR vs HELE Comparison

Compare CAPR & HELE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CAPR
  • HELE
  • Stock Information
  • Founded
  • CAPR 2005
  • HELE 1968
  • Country
  • CAPR United States
  • HELE United States
  • Employees
  • CAPR N/A
  • HELE N/A
  • Industry
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • HELE Home Furnishings
  • Sector
  • CAPR Health Care
  • HELE Consumer Discretionary
  • Exchange
  • CAPR Nasdaq
  • HELE Nasdaq
  • Market Cap
  • CAPR 600.7M
  • HELE 642.2M
  • IPO Year
  • CAPR N/A
  • HELE N/A
  • Fundamental
  • Price
  • CAPR $9.72
  • HELE $31.29
  • Analyst Decision
  • CAPR Strong Buy
  • HELE Buy
  • Analyst Count
  • CAPR 8
  • HELE 3
  • Target Price
  • CAPR $33.75
  • HELE $56.33
  • AVG Volume (30 Days)
  • CAPR 3.3M
  • HELE 536.0K
  • Earning Date
  • CAPR 08-06-2025
  • HELE 07-10-2025
  • Dividend Yield
  • CAPR N/A
  • HELE N/A
  • EPS Growth
  • CAPR N/A
  • HELE N/A
  • EPS
  • CAPR N/A
  • HELE 5.37
  • Revenue
  • CAPR $17,363,588.00
  • HELE $1,907,665,000.00
  • Revenue This Year
  • CAPR $258.96
  • HELE $0.44
  • Revenue Next Year
  • CAPR $8.02
  • HELE $0.99
  • P/E Ratio
  • CAPR N/A
  • HELE $5.30
  • Revenue Growth
  • CAPR N/A
  • HELE N/A
  • 52 Week Low
  • CAPR $3.52
  • HELE $24.15
  • 52 Week High
  • CAPR $23.40
  • HELE $93.09
  • Technical
  • Relative Strength Index (RSI)
  • CAPR 45.24
  • HELE 51.38
  • Support Level
  • CAPR $6.07
  • HELE $27.08
  • Resistance Level
  • CAPR $11.58
  • HELE $28.68
  • Average True Range (ATR)
  • CAPR 1.59
  • HELE 1.09
  • MACD
  • CAPR -0.23
  • HELE 0.31
  • Stochastic Oscillator
  • CAPR 44.57
  • HELE 62.95

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

About HELE Helen of Troy Limited

Helen Of Troy Ltd is a consumer products company offering creative products and solutions for its customers through a diversified portfolio of brands. It has two operating segments: Home and Outdoor segment provides a broad range of consumer products for home activities such as food preparation, cooking, cleaning, and organization; as well as products for outdoor and on-the-go activities such as hydration, food storage, backpacks, and travel gear, and The Beauty and Wellness segment provides beauty and wellness products including mass and prestige market beauty appliances, prestige market liquid-based hair and personal care products, and wellness devices including thermometers, water and air filtration systems, humidifiers, and fans.

Share on Social Networks: